Nucana Plc ADR (NCNA)

$3.34 +0.03 (0.91%)
Market Cap 101,000.00
Revenue (ttm) 0.00
Net Income (ttm) -24.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 34,700
Avg Vol 125,910
Day's Range N/A - N/A
Shares Out 30,000.00
Stochastic %K 10%
Beta 1.59
Analysts Strong Buy
Price Target $25.00

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 13 1357 1111
Address:
3 Lochside Way, Edinburgh, United Kingdom
AcquisitionArb
AcquisitionArb Dec. 25 at 3:41 PM
$NCNA Investors are recalibrating expectations as the balance shifts from vision to execution. Management alignment and prioritization play a larger role from here. Any disconnect between guidance and outcomes will magnify skepticism. Execution precision will determine whether this evolves or stalls.
1 · Reply
superstocksc
superstocksc Dec. 25 at 8:25 AM
$NCNA this is still so funny to me 😂💩 How the tables have turned
1 · Reply
FickleFin
FickleFin Dec. 25 at 2:27 AM
$NCNA players gonna play. Losers gonna lose...💩
1 · Reply
GreenEnergy1
GreenEnergy1 Dec. 25 at 2:09 AM
$NCNA Found a few posters using numerous alias. Bulls are so desperate… NCNA is trash!
1 · Reply
TVanda00
TVanda00 Dec. 24 at 4:26 PM
$NCNA
0 · Reply
Baseball89
Baseball89 Dec. 24 at 3:23 PM
$NCNA Merck needs this in their pipeline. They are on a buying spree. Andrew Kay we hope you can finalize everything before end of year . This could be a huge win for your company and investors.
0 · Reply
ParabolicalSpartan
ParabolicalSpartan Dec. 24 at 3:02 PM
What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems CABA $AFRM $NCNA $DXF --
0 · Reply
GuineaPigForever
GuineaPigForever Dec. 24 at 2:03 PM
$NCNA The bears posting here are just bitter bag holders. (the main two) Likely bought and went down with the reverse split crash. They are far to persistant to be simple short selling retail. They are constant enough to show their hand and their anger.
0 · Reply
cycloon
cycloon Dec. 24 at 10:11 AM
$NCNA All it takes is one positive message and we'll be off to a flying start.
0 · Reply
Baseball89
Baseball89 Dec. 24 at 2:25 AM
$NCNA Please stop listening to bears. Their job is to make you feel unworthy. Let's face it .....we know what we hold. We all know it's going to $5000 a share when news breaks. This CEO knows what he is doing. Be ready.....buy and hold. This will explode imo very soon.
3 · Reply
Latest News on NCNA
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Dec 10, 2025, 8:00 AM EST - 15 days ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 6 weeks ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Nov 5, 2025, 8:00 AM EST - 7 weeks ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 5, 2025, 8:00 AM EDT - 3 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Sep 3, 2025, 8:00 AM EDT - 4 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 20, 2025, 4:05 PM EDT - 4 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

NuCana Announces ADS Ratio Change

Aug 1, 2025, 4:05 PM EDT - 5 months ago

NuCana Announces ADS Ratio Change

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 21, 2025, 8:05 AM EDT - 5 months ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

NuCana Announces Plan to Implement ADS Ratio Change

Jul 11, 2025, 10:30 AM EDT - 5 months ago

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Jun 2, 2025, 4:01 PM EDT - 7 months ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 10 months ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Feb 10, 2025, 7:00 AM EST - 11 months ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 8:36 AM EDT - 1 year ago

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 1 year ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 1, 2024, 4:01 PM EDT - 1 year ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Apr 9, 2024, 4:30 PM EDT - 1 year ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

NuCana: Potential Turnaround In 2024 But Risky

Jan 3, 2024, 2:39 AM EST - 2 years ago

NuCana: Potential Turnaround In 2024 But Risky

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

NuCana to Present at the Jefferies London Healthcare Conference

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

NuCana to Present at the Jefferies Healthcare Conference

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 17, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Receipt of Nasdaq Notice

May 12, 2023, 4:01 PM EDT - 2 years ago

NuCana Announces Receipt of Nasdaq Notice

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 14, 2023, 8:00 AM EDT - 2 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Apr 4, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Mar 24, 2023, 4:30 PM EDT - 2 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

NuCana to Participate in Two Upcoming Investor Conferences

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

Jan 8, 2023, 4:30 AM EST - 3 years ago

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

NuCana Announces Receipt of NASDAQ Notice

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22, 2022, 3:40 PM EDT - 3 years ago

NuCana: An Intriguing 'Sum Of The Parts' Story

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 6, 2022, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Aug 31, 2022, 8:00 AM EDT - 3 years ago

NuCana to Participate in Citi's 17th Annual BioPharma Conference

AcquisitionArb
AcquisitionArb Dec. 25 at 3:41 PM
$NCNA Investors are recalibrating expectations as the balance shifts from vision to execution. Management alignment and prioritization play a larger role from here. Any disconnect between guidance and outcomes will magnify skepticism. Execution precision will determine whether this evolves or stalls.
1 · Reply
superstocksc
superstocksc Dec. 25 at 8:25 AM
$NCNA this is still so funny to me 😂💩 How the tables have turned
1 · Reply
FickleFin
FickleFin Dec. 25 at 2:27 AM
$NCNA players gonna play. Losers gonna lose...💩
1 · Reply
GreenEnergy1
GreenEnergy1 Dec. 25 at 2:09 AM
$NCNA Found a few posters using numerous alias. Bulls are so desperate… NCNA is trash!
1 · Reply
TVanda00
TVanda00 Dec. 24 at 4:26 PM
$NCNA
0 · Reply
Baseball89
Baseball89 Dec. 24 at 3:23 PM
$NCNA Merck needs this in their pipeline. They are on a buying spree. Andrew Kay we hope you can finalize everything before end of year . This could be a huge win for your company and investors.
0 · Reply
ParabolicalSpartan
ParabolicalSpartan Dec. 24 at 3:02 PM
What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems CABA $AFRM $NCNA $DXF --
0 · Reply
GuineaPigForever
GuineaPigForever Dec. 24 at 2:03 PM
$NCNA The bears posting here are just bitter bag holders. (the main two) Likely bought and went down with the reverse split crash. They are far to persistant to be simple short selling retail. They are constant enough to show their hand and their anger.
0 · Reply
cycloon
cycloon Dec. 24 at 10:11 AM
$NCNA All it takes is one positive message and we'll be off to a flying start.
0 · Reply
Baseball89
Baseball89 Dec. 24 at 2:25 AM
$NCNA Please stop listening to bears. Their job is to make you feel unworthy. Let's face it .....we know what we hold. We all know it's going to $5000 a share when news breaks. This CEO knows what he is doing. Be ready.....buy and hold. This will explode imo very soon.
3 · Reply
GreenEnergy1
GreenEnergy1 Dec. 23 at 7:53 PM
$NCNA Keep buying you fools... soon to be ZERO
0 · Reply
Oronero
Oronero Dec. 23 at 7:44 PM
$NCNA I recommend everyone buy this $CHR.X stock... A great company that a few months ago had a market capitalization of hundreds and hundreds of millions of dollars. Excellent revenue and over $200 million in cash. 4.6 million shares in free float. Offers underway and dilution over. Play your game🗽🚑
0 · Reply
TVanda00
TVanda00 Dec. 23 at 7:26 PM
$NCNA Outside perspective never bad
0 · Reply
superstocksc
superstocksc Dec. 23 at 1:56 PM
$NCNA 3,30$ touch?
0 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 1:24 AM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Lets spike them $NCNA $NVNI $GPUS $BURU
1 · Reply
HLucasH
HLucasH Dec. 22 at 7:15 PM
$NCNA serves you right😂😂 keep buying the deep!
0 · Reply
J_machete
J_machete Dec. 22 at 6:50 PM
$NCNA Why is this going down?? We had good data right.?
1 · Reply
TVanda00
TVanda00 Dec. 22 at 5:08 PM
$NCNA That bear flag cant break down right ?
1 · Reply
Panicmode
Panicmode Dec. 22 at 4:51 PM
$NCNA i see all the pumpers have just about vanished..
1 · Reply
GreenEnergy1
GreenEnergy1 Dec. 22 at 4:40 PM
$NCNA
0 · Reply
sidegains
sidegains Dec. 22 at 3:48 PM
$NCNA zero interest here
0 · Reply
FickleFin
FickleFin Dec. 22 at 3:23 PM
$NCNA 💩 stock.
0 · Reply